Vandetanib in Advanced NSCLC With RET Rearrangement
Status:
Completed
Trial end date:
2018-03-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the efficacy and safety of vandetanib, in
patients with advanced non-small-cell lung cancer harboring RET gene rearrangement. In 2011,
gene rearrangement between RET and KIF5B gene (fusion) was discovered in a young, male lung
cancer patient. The following studies showed that this gene rearrangement was critical for
tumor initiation and maintenance. Of note, the growth and signaling properties mediated by
KIF5B-RET were diminished after treatment with vandetanib.
Until now, RET rearrangements have been known in thyroid cancers. Vandetanib, a multi-kinase
inhibitors with anti-RET activity, is an FDA-approved drug for the treatments of adults with
metastatic medullary thyroid cancers who are ineligible for surgery and who have progressive
or symptomatic disease. This study aimed to examine the efficacy and safety of this drug, for
the treatment of advanced lung cancer harboring RET rearrangement.